FDA Drug Safety Communication Of Mirapex A Parkinson’s Drug

FDA Drug Safety Communication Of Mirapex A Parkinson’s Drug

Posted By The Maher Law Firm || 8-Mar-2013

Mirapex Tablets

The FDA (Food and Drug Administration) informed the public about the use of Mirapex (Pramipexole) and the risk of possible heart failure.

In an evaluation, the FDA analysed random clinical trials and found that heart failure was more frequent with Mirapex than with a placebo. Furthermore, two epidemiologic studies suggested that an increased risk of new onset heart failure occurred with Mirapex use. The FDA is continuing to work with the Mirapex manufacturer – Boehringer Ingelheim, to clarify further the risk of heart failure with Mirapex use.

Facts about Mirapex (Pramipexole):

  • Mirapex is a prescription medication used to treat signs and symptoms of Parkinson’s disease and restless leg syndrome
  • Mirapex is in a class of medications called “Dopamine Agonists”
  • Mirirapex acts as a replacement for dopamine. Parkinson’s disease causes progressive loss of dopamine production in the brain.

In a case controlled study among cohorts of users of anti-Parkinson’s drugs, aged 40 to 89 years – 783 heart failure cases were matched to 7,454 controls. The results showed that current use of any dopamine agonist (a substance that initiates a physiological response when combined with a receptor), versus no use of a dopamine agonist, was associated with statistically significant increase in the risk of heart failure. Among the individual dopamine agonists, a statistically significant association was found for Mirapex compared to no use fo these specific drugs.

If you believe that you or a loved one has suffered injury or death due to a defective or dangerous pharmaceutical, you may have a right to compensation for your injuries. The Maher Law Firm would like to help. We invite you to contact our trial-tested dangerous drug attorneys today.

Blog Home